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TheNR4A2/NURR1 gene (MIM*601828) has recently been associated with autosomal-dominant
early-onset dystonia-parkinsonism with intellectual disability.1 NR4A2 codifies for a nuclear tran-
scription factor and is expressed mainly in the substantia nigra, ventral tegmental area, and limbic
areas.2 To date, 14 different alterations in NR4A2 have been described associated with various
clinical phenotypes, mainly with neurodevelopment disorders (table e-1, links.lww.com/NXG/
A371). We describe here an interesting case suffering a persistent dystonia-parkinsonism syndrome
(DPS) with motor tics, which expands the clinical phenotype of NR4A2-associated DPS.
This is a 30-year-old man with no family history of neurologic disease who was born after a
normal pregnancy and childbirth. He started walking with support at 13 months, but his gait
was clumsy, resulting in numerous falls during childhood. At 2 years old, the patient presented
attention deficit. He began to speak at 3 years of age but with impaired fluency, vocabulary, and
articulation. The patient required special education to learn basic writing and arithmetic skills.
At the age of 7 years, his intelligence quotient was 77. At 16 years old, he presented tricho-
tillomania, and he began to experience motor tics characterized by an urge to move his right
shoulder upward, an urge that was relieved after performing the movement. He was satisfac-
torily treated with atomoxetine. He also noticed an abnormal backward-cervical deviation. This
clinical situation remained stable for 10 years, although motor tics tended to improve with age.
At 28 years old, the patient complained of slowness, walking difficulties, and a worsening
abnormal craniocervical posture. He presented marked jaw-opening dystonia and parkinsonian
features, with rigidity and a progressive reduction in the amplitude and frequency of repetitive
movements in the left hemibody. The gait difficulties manifested with dragging steps, mainly in
the left hemibody (Video 1). The patient also presented nonmotor symptoms such as gas-
trointestinal and sleep-related symptoms, with the mobility and communication domains af-
fecting his quality of life the most (figures e-1 and e-2, links.lww.com/NXG/A371).
The results of supplementary and neuroimaging tests were normal (figure 1, table e-2, links.
lww.com/NXG/A371), whereas 123FP-CIT-single photon emission CT revealed reduced bi-
lateral (predominantly right sided) uptake in both striatum (figure e-1).
A genetic analysis using a custom gene panel of 498 genes involved in movement disorders
(MovDisord-498)3 revealed no causative mutations (appendix e-1, links.lww.com/NXG/
A371). The proband and healthy parents (trio) then underwent whole exome sequencing
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(WES) using the Whole Exome Family Plus test (Blueprint
Genetics, Helsinki, Finland). WES data were filtered as pre-
viously described4 and 3 candidate disease-causing changes
were found (table e-3). We further investigated the detected
changes by Sanger sequencing in all the available relatives
(figure e-3). The KCNQ2 c.1807-5A>T resulted to be a false-
positive result. The proband, his parents, and his brother
carried the CEP170 c.2375C>A (p.S792*) change in hetero-
zygosis, and therefore, this variant was discarded as disease-
causing mutation. Regarding the NR4A2 c.956G>A
(p.R319Q) substitution, only the patient harbored it, and
consequently, this mutation was de novo. Moreover, 2
frameshift mutations in NR4A2 were recently described in 2
patients with DPS.1 R319 is an evolutionarily conserved
amino acid (data not shown) located on the essential domain
Zf-C4/DBD (figure e-4). The variant was considered likely
pathogenic according to the American College of Medical
Genetics and Genomics classification, based mainly on the
PS2 and PM2 criteria, although the NR4A2 c.956G>A mu-
tation also meets the PP3 and PM1 criteria.5
Consistent with previous descriptions of NR4A2 subjects,1
our patient also presented craniocervical dystonia with par-
kinsonian features that started in early adulthood, with pre-
vious intellectual disability and language impairment. In our
proband, however, the dystonia was persistent and worsened
in stressful situations, contrasting with the previously reported
paroxysmal dystonic episodes.1 Clinicians should therefore be
aware of paroxysmal and persistent dystonia features related
to NR4A2.
Our proband also shared with previously reported cases, clear
signs, and symptoms of dopaminergic degeneration,1 suggest-
ing a relationship between the role of NR4A2 and dysfunction
of the dopaminergic nigrostriatal network. Of interest, our
patient also experienced motor tics and attention deficit during
childhood. Previous reports have shown the involvement of
gross deletions in NR4A2 in autism spectrum disorders, with
some patients manifesting “restlessness” during childhood.6 To
date, however, there have been no reported data on the
comorbidity with motor tics, which are therefore a novel fea-
ture associated with the NR4A2 phenotype, a feature that will
become clearer as more cases are reported.
In NR4A2, there seems to be no association between the
mutation type and the resulting phenotype, except for pa-
tients with complex neurodevelopmental disorders that are
caused by large deletions. In fact, diverse NR4A2-related
phenotypes can even be caused by the same mutation.7 In this
case study, we presented the first patient with DPS caused by a
missense NR4A2 mutation, the p.R319Q. NR4A2-associated
DPS can therefore be caused by more than just loss-of-
function mutations.
In conclusion, motor tics and persistent dystonia in NR4A2-
associated DPS should be included within its phenotypic
description along with early-onset parkinsonism and in-
tellectual disability with language impairment. The de-
scription of new cases may help to improve the correlation
between NR4A2 and its clinical picture, which, so far, is
mainly relevant for neurodevelopmental disorders.
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Figure 1 Functional and Structural Brain Images
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putamen. (B and C) Normal 18FDG-PET coronal and axial images. (D) Normal cranial MRI T2 axial image. 18FDG = 18-fluorodeoxyglucose.
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